Oncogenetic counseling in Brazil

reality and perspectives

Abstract

Since 2015, genetic testing for germline mutation in high risk patients, according to international criteria for hereditary cancer, is of mandatory coverage by national private health insurance. Although this timid progress, the current reality is still far beyond the screening programs of the United States and other developed countries. This article will discuss relevant issues about the policy of screening and about the training of medical and non-medical professionals in the practice of oncogenetic counseling.